S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NYSE:ZYME

Zymeworks - ZYME Stock Forecast, Price & News

$7.43
+0.46 (+6.60%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.93
$7.53
50-Day Range
$5.30
$7.43
52-Week Range
$4.56
$37.19
Volume
556,403 shs
Average Volume
1.40 million shs
Market Capitalization
$430.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.13

Zymeworks MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
278.5% Upside
$28.13 Price Target
Short Interest
Healthy
19.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.69) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

869th out of 1,117 stocks

Pharmaceutical Preparations Industry

434th out of 550 stocks

ZYME stock logo

About Zymeworks (NYSE:ZYME) Stock

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Analyst Ratings Changes

ZYME has been the subject of several research analyst reports. SVB Leerink lifted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company an "outperform" rating in a research report on Friday, May 27th. HC Wainwright dropped their price target on Zymeworks from $44.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, May 23rd. Finally, Guggenheim upgraded Zymeworks from a "neutral" rating to a "buy" rating and set a $14.00 price objective on the stock in a research report on Thursday, May 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.13.

Zymeworks Trading Up 1.6 %

Shares of NYSE:ZYME opened at $6.97 on Friday. The company has a market cap of $403.49 million, a price-to-earnings ratio of -1.60 and a beta of 1.14. Zymeworks has a 12 month low of $4.56 and a 12 month high of $37.19. The company has a 50-day moving average price of $6.11 and a 200-day moving average price of $6.49.

Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Stock News Headlines

Stop Day Trading - More Here
Jeff Clark - "I Never Worry About Where The Market Is Headed. I Only Trade One Stock". Learn More. pixel
One Stock Is All You Need 
Step-by-step guide to trading - and winning - in any market conditions with just ONE stock. Learn More. pixel
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Company Calendar

Last Earnings
11/03/2021
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:ZYME
Employees
455
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.13
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+278.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Margins
-749.38%
Pretax Margin
-751.56%

Debt

Sales & Book Value

Annual Sales
$26.68 million
Book Value
$3.84 per share

Miscellaneous

Free Float
54,917,000
Market Cap
$430.14 million
Optionable
Optionable
Beta
1.14

Key Executives














ZYME Stock - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYME shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price forecast for 2022?

7 equities research analysts have issued 12-month price objectives for Zymeworks' stock. Their ZYME share price forecasts range from $14.00 to $48.00. On average, they predict the company's share price to reach $28.13 in the next twelve months. This suggests a possible upside of 278.5% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2022?

Zymeworks' stock was trading at $16.39 at the beginning of 2022. Since then, ZYME stock has decreased by 54.7% and is now trading at $7.43.
View the best growth stocks for 2022 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ZYME earnings forecast
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) released its earnings results on Wednesday, November, 3rd. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $0.08. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $8.80 million. Zymeworks had a negative net margin of 749.38% and a negative trailing twelve-month return on equity of 91.78%.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (4.22%), Cowen AND Company LLC (2.60%), Timelo Investment Management Inc. (1.60%), CI Investments Inc. (0.59%), Lynwood Capital Management Inc. (0.52%) and Platinum Investment Management Ltd. (0.51%). Insiders that own company stock include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, Neil A Klompas, Neil Josephson and Troy Cox.
View institutional ownership trends
.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $7.43.

How much money does Zymeworks make?

Zymeworks (NYSE:ZYME) has a market capitalization of $430.14 million and generates $26.68 million in revenue each year.

How many employees does Zymeworks have?

The company employs 455 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (604) 678-1388, via email at ir@zymeworks.com, or via fax at 604-737-7077.

This page (NYSE:ZYME) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.